Versartis Inc. Cmn (VSAR) 10.75 $VSAR Versartis Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Versartis Inc. Cmn (VSAR) 10.75 $VSAR

Versartis Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 3:05PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the second quarter ended June 30, 2016 and provided an update on its clinical development programs.
VSAR: 10.75 (-0.49)

Versartis Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2016.
VSAR: 10.75 (-0.49)

The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
VSAR: 10.75 (-0.49), IBKR: 34.46 (-0.67), AXDX: 19.98 (-0.54), ONCE: 55.96 (-2.91), YRD: 25.44 (-2.86)

5 Stocks with Rising Analyst Coverage
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 3:54PM CDT
New or increased coverage on a stock is usually the result of huge investor focus on it.
VSAR: 10.75 (-0.49), IBKR: 34.46 (-0.67), AXDX: 19.98 (-0.54), ONCE: 55.96 (-2.91), YRD: 25.44 (-2.86)

Versartis (VSAR) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:51AM CDT
As of late, it has definitely been a great time to be an investor in Versartis Inc (VSAR)
VSAR: 10.75 (-0.49)

Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
GlobeNewswire - Mon Apr 04, 7:30AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that Year 2 safety and efficacy data from its ongoing Extension Study of somavaratan in children with GHD were presented yesterday in a late-breaker oral presentation at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. George Bright, MD, Versartis' Global Pediatric Clinical Development Advisor, presented the results at the late breaker oral session (LB-OR02-2) titled "Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): Results at 2 Years" on Sunday, April 3, 2016.
VSAR: 10.75 (-0.49)

Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
GlobeNewswire - Fri Apr 01, 6:00AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that adherence data from its ongoing Extension Study of somavaratan in children with GHD will be presented today in a late-breaker poster presentation at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. Eric Humphriss, MBA, Vice President of Clinical Operations at Versartis, will discuss the results at the Late Breaker poster session (poster LBFri-01) on Friday, April 1, 2016 from 1:15 p.m. - 3:15 p.m. Eastern Time (ET).
VSAR: 10.75 (-0.49)

Versartis Appoints Colin Hislop, M.D., as Chief Medical Officer
GlobeNewswire - Wed Mar 30, 7:30AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it has appointed Colin Hislop, M.D. as Chief Medical Officer. Dr. Hislop is an experienced drug development clinician with over 27 years of experience in both pharmaceutical and biotechnology companies.
VSAR: 10.75 (-0.49)

Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society's 98th Annual Meeting
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that detailed two-year, safety, efficacy and adherence data from its ongoing Extension Study of somavaratan in children with GHD will be featured in two late-breaker presentations at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), to be held April 1-4, 2016, in Boston, MA. The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children.
VSAR: 10.75 (-0.49)

Capella Bioscience Completes Series A Financing of GBP11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire Europe - Tue Mar 08, 3:01AM CST
LONDON, March 8, 2016 /PRNewswire/ --
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)

Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire - Tue Mar 08, 3:00AM CST
Capella Bioscience Ltd. announced today the close of a £11 million ($15.5 million), Series A financing round. The round was financed by Advent Life Sciences, Medicxi Ventures, and Osage University Partners. The new capital will support continued advancement of the company's novel therapeutic antibody discovery programs towards clinical evaluation.
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)

Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a EUR210m Fund including GSK and Johnson & Johnson Innovation
PR Newswire Europe - Tue Feb 02, 12:01AM CST
LONDON, GENEVA and JERSEY, February 2, 2016 /PRNewswire/ --
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)

Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan
GlobeNewswire - Thu Jan 28, 3:05PM CST
Conference Call and Webcast Featuring Guest Speaker Dr. Bradley Miller Scheduled at 7:30 a.m. ET on February 2, 2016
VSAR: 10.75 (-0.49)

Versartis' VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism
GlobeNewswire - Wed Dec 16, 12:38PM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that results of a Phase 1b/2a pediatric trial of the investigational drug, somavaratan, were published online in The Journal of Clinical Endocrinology & Metabolism (JCEM) entitled "A Randomized Safety and Efficacy Study of somavaratan, a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency" .
VSAR: 10.75 (-0.49)

Direction of Market Influences - Analyst Notes on Maxwell Technologies, Organovo Holdings, Abraxas Petroleum and Versartis
ACCESSWIRE - Wed Dec 16, 7:26AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Maxwell Technologies Inc. (NASDAQ: MXWL), Organovo Holdings Inc. (NYSE: ONVO), Abraxas Petroleum Corp (NASDAQ: AXAS) and Versartis Inc. (NASDAQ: VSAR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MXWL: 5.25 (-0.07), VSAR: 10.75 (-0.49), ONVO: 4.20 (-0.17), AXAS: 1.11 (-0.01)

Growth Hormone Deficiency - Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cpvstr/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Ascendis Pharma A/S - Biogenomics Limited - Bolder Biotechnology, Inc. - Braasch Biotech LLC - Carlina Technologies SAS - Critical Pharmaceuticals Limited - Delpor, Inc. - Flamel Technologies S.A. - Genexine, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Inbiopro Solutions Pvt. Ltd. - JCR Pharmaceuticals Co., Ltd. - LG Life Sciences Limited - OPKO Health, Inc. - Pfenex Inc. - Prometheon Pharma, LLC - Teva Pharmaceutical Industries Limited - Versartis, Inc. - XL-protein GmbH For more information visit http://www.researchandmarkets.com/research/cp...th_hormone
VSAR: 10.75 (-0.49), FLML: 12.53 (-0.11), ASND: 13.96 (-0.11), OPK: 9.90 (-0.17), TEVA: 53.20 (-0.41), PFNX: 8.49 (-0.11)

Versartis to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Tue Nov 03, 3:16PM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that Mr. Jay Shepard, President and Chief Executive Officer, is scheduled to present at the Credit Suisse 24 Annual Healthcare Conference on Tuesday, November 10 in Scottsdale, Arizona.
VSAR: 10.75 (-0.49)

Versartis reports 3Q loss
Automated Insights - Thu Oct 29, 5:31PM CDT
MENLO PARK, Calif. (AP) _ Versartis Inc. (VSAR) on Thursday reported a loss of $20.4 million in its third quarter.
VSAR: 10.75 (-0.49)

Versartis Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Oct 29, 3:06PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the third quarter and nine months ended September 30, 2015.
VSAR: 10.75 (-0.49)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading